Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage Guideline must be read in its entirety to determine coverage eligibility, if any.

This Medical Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide BCBSAZ complete medical rationale when requesting any exceptions to these guidelines.

The section identified as “Description” defines or describes a service, procedure, medical device or drug and is in no way intended as a statement of medical necessity and/or coverage.

The section identified as “Criteria” defines criteria to determine whether a service, procedure, medical device or drug is considered medically necessary or experimental or investigational.

State or federal mandates, e.g., FEP program, may dictate that any drug, device or biological product approved by the U.S. Food and Drug Administration (FDA) may not be considered experimental or investigational and thus the drug, device or biological product may be assessed only on the basis of medical necessity.

Medical Coverage Guidelines are subject to change as new information becomes available.

For purposes of this Medical Coverage Guideline, the terms "experimental" and "investigational" are considered to be interchangeable.

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.
TOTAL ANKLE REPLACEMENT (cont.)

Description:

Total ankle replacement or revision with implant of artificial ankle prosthesis. Total ankle replacement may also be referred to as total ankle arthroplasty.

In general, individuals selected for arthroplasty would not be good candidates for arthrodesis (joint fusion) due to the presence of bilateral or subtalar arthritis or Chopart arthrosis. Optimal candidates for total ankle replacement are considered to be older (age older than 50), thin, low-demand individuals with minimal deformity. Individuals should have no functional barriers to participation in a rehabilitation program. Total ankle arthroplasty is intended to give a patient limited mobility by reducing pain, restoring alignment and replacing the flexion and extension movement in the ankle joint. Total ankle arthroplasty is indicated for patients with ankle joints damaged by severe rheumatoid, post traumatic or degenerative arthritis. Additionally indicated for patients with a failed previous ankle surgery.

Device names intended for cemented use only include, but are not limited to:

- Agility® Ankle Revision Prosthesis
- Eclipse Total Ankle Implant
- Inbone® and Infinity® Total Ankle Systems
- Integra Total Ankle Replacement System
- Invision® Total Ankle Revision System
- Salto Talaris® Total Ankle Prosthesis
- Vantage™ Total Ankle System

Device names intended for non-cemented use only include, but are not limited to:

- Scandinavian Total Ankle Replacement System (S.T.A.R.® Ankle)
TOTAL ANKLE REPLACEMENT (cont.)

Criteria:

- Total ankle replacement using an FDA-approved device is considered *medically necessary* with documentation of **ALL** of the following:
  1. Individual is skeletally mature (radiographic evidence of epiphyseal closure)
  2. Moderate to severe ankle (tibiotalar) pain that limits daily activity
  3. **ANY** of the following:
     - Arthritis in adjacent joints (i.e., subtalar or midfoot)
     - Arthrodesis of the contralateral ankle
     - Inflammatory (e.g., rheumatoid) arthritis
     - Severe arthritis of the contralateral ankle
  4. Absence of **ALL** the following absolute contraindications:
     - Active ankle joint infection
     - Charcot neuroarthropathy
     - Compromised bone stock or soft tissue (including skin and muscle)
     - Extensive avascular necrosis of the talar dome
     - Peripheral vascular disease
     - Severe malalignment (e.g., >15 degrees) not correctable by surgery

- Medical director and/or clinical advisor review is required for **ANY** of the following relative contraindications:
  - History of ankle joint infection
  - Ligamentous instability
  - Peripheral neuropathy
  - Presence of severe deformities above or beneath the ankle
  - Subluxation of the talus
  - Vascular insufficiency

- Total ankle replacement for all other indications not previously listed or if above criteria not met is considered *experimental or investigational* based upon:
  1. Insufficient scientific evidence to permit conclusions concerning the effect on health outcomes, and
  2. Insufficient evidence to support improvement of the net health outcome, and
  3. Insufficient evidence to support improvement of the net health outcome as much as, or more than, established alternatives.
TOTAL ANKLE REPLACEMENT (cont.)

Resources:

Literature reviewed 08/02/16. We do not include marketing materials, poster boards and non-published literature in our review.

The BCBS Association Medical Policy Reference Manual (MPRM) policy is included in our guideline review. References cited in the MPRM policy are not duplicated on this guideline.


TOTAL ANKLE REPLACEMENT (cont.)

**Resources:** (cont.)


TOTAL ANKLE REPLACEMENT (cont.)

Resources: (cont.)


TOTAL ANKLE REPLACEMENT (cont.)

Resources: (cont.)

